Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EDIT Editas Medicine

Market Closed 07-24 16:00:00 EDT

2.60

-0.13

-4.76%

盘后2.59

-0.01-0.38%

19:34 EDT

High2.76	Low2.59	Vol1.52M
Open2.75	D1 Closing2.73	Amplitude6.04%
Mkt Cap397.80M	Tradable Cap368.78M	Total Shares153.00M
T/O4.01M	T/O Rate1.07%	Tradable Shares141.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EDIT","market":"US","secType":"STK","nameCN":"Editas Medicine","latestPrice":2.6,"timestamp":1784923200000,"preClose":2.73,"halted":0,"volume":1516741,"hourTrading":{"tag":"盘后","latestPrice":2.59,"preClose":2.6,"latestTime":"19:34 EDT","volume":20316,"amount":52857.068,"timestamp":1784936046929,"change":-0.01,"changeRate":-0.003846,"amplitude":0.0375},"delay":0,"changeRate":-0.04761904761904758,"floatShares":141837682,"shares":153000000,"eps":-1.178492,"marketStatus":"Market Closed","change":-0.13,"latestTime":"07-24 16:00:00 EDT","open":2.75,"high":2.755,"low":2.59,"amount":4006424.6358772,"amplitude":0.06044,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.178492,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.73,"preHourTrading":{"tag":"盘前","latestPrice":2.77,"preClose":2.73,"latestTime":"07:35 EDT","volume":426,"amount":1203.4517039999998,"timestamp":1784892918813,"change":0.04,"changeRate":0.014652,"amplitude":0.025641},"postHourTrading":{"tag":"盘后","latestPrice":2.59,"preClose":2.6,"latestTime":"19:34 EDT","volume":20316,"amount":52857.068,"timestamp":1784936046929,"change":-0.01,"changeRate":-0.003846,"amplitude":0.0375},"volumeRatio":1.1195941018409594,"impliedVol":0.773,"impliedVolPercentile":0.2271},"requestUrl":"/m/hq/s/EDIT","defaultTab":"news","newsList":[{"id":"2651195898","title":"Genflow Appoints Gad Berdugo as Independent Non-executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2651195898","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651195898?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:00","pubTimestamp":1783922433,"startTime":"0","endTime":"0","summary":"Genflow appoints Gad Berdugo as independent non-executive chairmanGenflow named Gad Berdugo as independent non-executive chairman in January 2026.Berdugo brings more than 30 years of biotech leadershi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL2hDq84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","EDIT","BK5083","GENF.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644031775","title":"Editas Medicine Shareholders Back Board, Pay and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2644031775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644031775?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:50","pubTimestamp":1781819405,"startTime":"0","endTime":"0","summary":"An announcement from Editas Medicine ( ($EDIT) ) is now available. At its June 17, 2026 annual meeting, Editas Medicine stockholders elected Bernad...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-medicine-shareholders-back-board-pay-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-medicine-shareholders-back-board-pay-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644036719","title":"Editas Medicine shareholders elect Connaughton, Levy as Class I directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644036719","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644036719?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:29","pubTimestamp":1781814564,"startTime":"0","endTime":"0","summary":"Editas Medicine held its 2026 annual stockholders meeting on June 17, 2026.Stockholders backed the board’s director slate, resulting in Bernadette Connaughton and Elliott Levy, M.D., serving as Class I directors through 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL8q1ZRv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639661684","title":"Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639661684","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639661684?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:01","pubTimestamp":1779998460,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303236/0/en/Editas-Medicine-Announces-Updated-Presentation-Time-for-Upcoming-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638768210","title":"Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2638768210","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638768210?lang=en_us&edition=fundamental","pubTime":"2026-05-28 00:33","pubTimestamp":1779899629,"startTime":"0","endTime":"0","summary":"After Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the Eu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-preclinical-data-looks-highly-supportive-says-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-preclinical-data-looks-highly-supportive-says-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638569682","title":"TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’","url":"https://stock-news.laohu8.com/highlight/detail?id=2638569682","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638569682?lang=en_us&edition=fundamental","pubTime":"2026-05-28 00:16","pubTimestamp":1779898611,"startTime":"0","endTime":"0","summary":"TD Cowen notes that Editas Medicine (EDIT) presented “compelling preclinical data” at EAS detailing EDIT-401’s 90% reduction in low-density lipopro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/td-cowen-remains-bullish-on-editas-medicine-after-compelling-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/td-cowen-remains-bullish-on-editas-medicine-after-compelling-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4566","BK4585","TD","BK4127","COWN","BK4556","BK4207","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638548693","title":"BUZZ-Editas Medicine down after $125 mln stock-and-warrants offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2638548693","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638548693?lang=en_us&edition=fundamental","pubTime":"2026-05-26 22:05","pubTimestamp":1779804332,"startTime":"0","endTime":"0","summary":"BUZZ-Editas Medicine down after $125 mln stock-and-warrants offeringUpdates with pricing details** Gene editing firm Editas Medicine EDIT.O shares down 0.7% to $2.74 in early Tues trading after follow-on priced** Cambridge, Massachusetts EDIT announces ~55.56 mln shares and accompanying warrants at $2.25 for $125 mln gross proceeds** Offering price represents 18.5% discount to stock's last close on Fri** EDIT would collect another $194.4 mln in gross proceeds if all the warrants are exercised at their exercise price of $3.50** Warrants are exercisable under certain conditions, including following announced Phase 1 clinical data for product candidate, EDIT-401** Earlier Tues, EDIT said it presented preclinical EDIT-401 data at the European Atherosclerosis Society Congress on May 25 that achieved robust reductions in LDL-cholesterol, lipoprotein and apolipoprotein B in non-human primates** Co intends to use net offering proceeds for EDIT-401, including clinical development and manufactur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nL6N4230P1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638517698","title":"Editas Medicine Announces Pricing of up to $319.4 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2638517698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638517698?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:05","pubTimestamp":1779800727,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA5VMM8K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638517660","title":"Editas Medicine Inc - Prices Public Offering of 55.56 Mln Shares and Warrants at $2.25 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2638517660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638517660?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:05","pubTimestamp":1779800727,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA5VMM8K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638517956","title":"Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2638517956","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638517956?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:05","pubTimestamp":1779800700,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May  26, 2026  (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3301169/0/en/Editas-Medicine-Announces-Pricing-of-Up-to-319-4-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638126665","title":"Editas Medicine Suspends Existing At-The-Market Offering Prospectus","url":"https://stock-news.laohu8.com/highlight/detail?id=2638126665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638126665?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:31","pubTimestamp":1779798675,"startTime":"0","endTime":"0","summary":"Editas Medicine ( ($EDIT) ) has issued an update. On May 26, 2026, Editas Medicine, Inc. suspended and terminated the March 21, 2025 prospectus sup...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-medicine-suspends-existing-at-the-market-offering-prospectus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-medicine-suspends-existing-at-the-market-offering-prospectus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638944515","title":"Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2638944515","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638944515?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:38","pubTimestamp":1779791910,"startTime":"0","endTime":"0","summary":"Editas Medicine  has commenced an underwritten public offering of common stock and pre-funded warrants, along with accompanying warrants to purchase additional shares, the gene editing company said Tuesday.The company said it has not yet determined the actual size or terms of the offering.The company's shares were down 18% in recent Tuesday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515284","title":"Editas Showcases Promising EDIT-401 Data for Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638515284?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:35","pubTimestamp":1779791748,"startTime":"0","endTime":"0","summary":"The latest update is out from Editas Medicine ( ($EDIT) ). On May 25, 2026, Editas Medicine presented new preclinical data at the 94th European Ath...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-showcases-promising-edit-401-data-for-hyperlipidemia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-showcases-promising-edit-401-data-for-hyperlipidemia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","EPV","BK4139","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638134405","title":"Editas Medicine launches underwritten follow-on stock offering with warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2638134405","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638134405?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:15","pubTimestamp":1779790537,"startTime":"0","endTime":"0","summary":"Editas Medicine launched an underwritten public offering of common stock or pre-funded warrants.The deal includes accompanying warrants to buy common stock, with pre-funded warrants available in lieu of shares.Cantor Fitzgerald and Wells Fargo Securities are joint book-running managers.Pricing, size, and timing were not disclosed; completion depends on market conditions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL1RFGJb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","SG9999014039.USD","BK4139","IE00BGHQF748.EUR","BK4556","SG9999014013.SGD","BK4112","IE00BN0W2T93.GBP","BK4585","LU2210150020.SGD","EDIT","IE00BN0W2V16.EUR","NDAQ","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638951345","title":"Editas Medicine Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2638951345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638951345?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:15","pubTimestamp":1779790503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUABMCS2D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638725513","title":"Editas Medicine presented preclinical data for EDIT-401 at EAS Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2638725513","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638725513?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:14","pubTimestamp":1779790447,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the 94th Eur...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-presented-preclinical-data-for-edit-401-at-eas-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-presented-preclinical-data-for-edit-401-at-eas-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638568513","title":"Editas Medicine presents preclinical EDIT-401 data showing about 90% LDL-C reduction in primate study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638568513","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638568513?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:03","pubTimestamp":1779789791,"startTime":"0","endTime":"0","summary":"Editas Medicine presented preclinical EDIT-401 data at the European Atherosclerosis Society Congress on May 25, 2026.The single-dose gene-editing candidate produced broad, rapid reductions across key atherogenic lipoproteins in non-human primates.Editas targets a mid-2026 Clinical Trial Notification filing, with early in vivo human proof-of-concept data expected by end-2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL8rxxHy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","BK4139","BK4585","BK4112","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","BK4556","IE00BGHQF748.EUR","EDIT","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638418513","title":"Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2638418513","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638418513?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:01","pubTimestamp":1779789660,"startTime":"0","endTime":"0","summary":"Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent eff","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300882/0/en/Editas-Medicine-Presents-EDIT-401-Preclinical-Data-Demonstrating-Robust-Reductions-in-LDL-C-Lp-a-and-ApoB-in-Non-Human-Primates-at-the-94th-European-Atherosclerosis-Society-Congres.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","EPV","LDL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635740001","title":"Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635740001","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635740001?lang=en_us&edition=fundamental","pubTime":"2026-05-15 02:57","pubTimestamp":1778785068,"startTime":"0","endTime":"0","summary":"The analysts covering Editas Medicine, Inc. ( NASDAQ:EDIT ) delivered a dose of negativity to shareholders today, by...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/analyst-forecasts-just-became-more-bearish-on-editas-medicin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/analyst-forecasts-just-became-more-bearish-on-editas-medicin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TQQQ","QQQY",".IXIC","SQQQ","FTEC","QQQJ","NVIW.SI","EDIT","IYW","QYLG","BK4139","QLD","QID","QDTE","NQmain","TQQY","TECS","JEPQ","QQQM","NDX","BK4556","PSQ","MNQmain","ONEQ","QQQE","QQQA","GPIQ","QQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635874635","title":"JonesTrading Keeps Their Buy Rating on Editas Medicine (EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635874635","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635874635?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:35","pubTimestamp":1778769333,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Editas Medicine, with a price target of $8.00. Peaker covers ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-keeps-their-buy-rating-on-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.editasmedicine.com","stockEarnings":[{"period":"1week","weight":-0.1275},{"period":"1month","weight":-0.0714},{"period":"3month","weight":-0.1065},{"period":"6month","weight":0.2037},{"period":"1year","weight":-0.2025},{"period":"ytd","weight":0.2683}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.048743},{"month":2,"riseRate":0.5,"avgChangeRate":0.075357},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.053873},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.002841},{"month":5,"riseRate":0.545455,"avgChangeRate":0.014988},{"month":6,"riseRate":0.545455,"avgChangeRate":0.075904},{"month":7,"riseRate":0.636364,"avgChangeRate":0.014387},{"month":8,"riseRate":0.6,"avgChangeRate":0.036188},{"month":9,"riseRate":0.2,"avgChangeRate":-0.076361},{"month":10,"riseRate":0.4,"avgChangeRate":-0.058936},{"month":11,"riseRate":0.5,"avgChangeRate":0.071042},{"month":12,"riseRate":0.3,"avgChangeRate":0.023099}],"exchange":"NASDAQ","name":"Editas Medicine","nameEN":"Editas Medicine"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Editas Medicine,EDIT,Editas Medicine股票,Editas Medicine股票老虎,Editas Medicine股票老虎国际,Editas Medicine行情,Editas Medicine股票行情,Editas Medicine股价,Editas Medicine股市,Editas Medicine股票价格,Editas Medicine股票交易,Editas Medicine股票购买,Editas Medicine股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}